Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

278.80 -6.60 (-2.31%) 市場開市。 截至 01:34PM CEST。

Swedish Orphan Biovitrum AB (publ)

Tomtebodavägen 23A
Solna 112 76
Sweden
46 86 97 20 00
https://www.sobi.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 1,752

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Guido Oelkers	CEO & President	25.82M	無	1965
Mr. Henrik Stenqvist	Chief Financial Officer	無	無	1967
Mr. Torbjörn Hallberg	General Counsel & Head of Legal Affairs	無	無	1969
Mr. Daniel Rankin	Head of Strategy & Corporate Development	無	無	1980
Ms. Lena Bjurner	Head of Human Resources	無	無	1968
Mr. Armin Reininger M.D., Ph.D.	Senior Scientific & Medical Advisor	無	無	1957
Mr. Norbert Oppitz	Head of International	無	無	1967
Mr. Sofiane Fahmy	Head of Europe	無	無	1972
Mr. Duane H. Barnes	Head of North America	無	無	1960
Mr. Mahmood Ladha	Head of Strategic Transformation Operations	無	無	1964

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 SEK。

描述

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

公司管治

截至 2024年4月29日 止，Swedish Orphan Biovitrum AB (publ) 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：3；董事會：7；股東權利：1；現金賠償：2。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。